A review of trials published during 2010–2018 described different treatment time courses. Earlier symptom change with clonazepam in a cited comparison did not establish superior outcomes at every later assessment.
The authors searched several databases and included prospective experimental studies with more than ten participants. The selected literature mixed randomized, open-label, and comparative designs.
The review described clonazepam and paroxetine comparisons in which earlier improvement favored clonazepam, while later global clinical measures and panic-attack counts did not show the same between-group difference. It also reported no clear efficacy difference between sublingual and conventional alprazolam in an included study.
A rapid effect and a sustained effect are different outcomes. Open-label comparisons can be influenced by expectations and treatment selection, and the review’s narrow date window does not represent every historical trial.
The paper did not establish that all formulations are pharmacokinetically interchangeable or that a favorable symptom trajectory resolves long-term dependence and discontinuation questions.
Identify the particular comparison, follow-up period, and outcome before describing a medicine as better. A patient’s ongoing panic symptoms also need assessment beyond whether a benzodiazepine produced early relief. The review supports a time-sensitive account of the evidence rather than a universal ranking of treatments.
Original analysis of the supplied journal article, identified as PMC6354041.